EUR 0.87
(-3.89%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 17.11 Million EUR | -21.41% |
2022 | 13.41 Million EUR | 31.78% |
2021 | 10.18 Million EUR | 71.03% |
2020 | 5.95 Million EUR | 29.67% |
2019 | 4.59 Million EUR | 14.35% |
2018 | 4.01 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 3.43 Million EUR | -23.45% |
2024 Q2 | 3.5 Million EUR | 2.15% |
2024 Q3 | 3.16 Million EUR | -9.83% |
2023 FY | 10.54 Million EUR | -21.41% |
2023 Q4 | 4.48 Million EUR | 0.0% |
2023 Q1 | 3.66 Million EUR | -9.04% |
2023 Q3 | 4.48 Million EUR | 23.82% |
2023 Q2 | 3.62 Million EUR | -1.12% |
2022 Q3 | 4.02 Million EUR | 26.67% |
2022 Q4 | 4.02 Million EUR | 0.0% |
2022 FY | 13.41 Million EUR | 31.78% |
2022 Q2 | 3.18 Million EUR | 6.21% |
2022 Q1 | 2.99 Million EUR | -50.78% |
2021 Q4 | 6.08 Million EUR | 328.11% |
2021 FY | 10.18 Million EUR | 71.03% |
2021 Q3 | 1.42 Million EUR | 47.56% |
2021 Q2 | 963 Thousand EUR | -10.75% |
2021 Q1 | 1.07 Million EUR | -42.88% |
2020 Q3 | 1.35 Million EUR | 0.0% |
2020 FY | 5.95 Million EUR | 29.67% |
2020 Q4 | 1.88 Million EUR | 39.62% |
2019 FY | 4.59 Million EUR | 14.35% |
2018 FY | 4.01 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BBS-Bioactive Bone Substitutes Oyj | 3.36 Million EUR | -408.912% |
Nexstim Plc | 3.51 Million EUR | -386.75% |
Revenio Group Oyj | 18.8 Million EUR | 8.963% |